Group items tagged

The global film dressing market size is anticipated to reach USD 2,165.41 million by 2030, registering a CAGR of 4.54% during the forecast period, according to a new report by Grand View Research, Inc.

The global cell-based assays market size was valued at USD 15.95 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 8.75% from 2022 to 2030

The global specimen containers market size was valued at USD 2.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.85% from 2022 to 2030.

The global clinical trial investigative site network market size is expected to reach USD 12.5 billion by 2030, registering a CAGR of 6.0% over the forecast period, according to a new report by Grand View Research, Inc.

The U.S. infections imaging market size was valued at USD 29.72 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.3% from 2022 to 2030

The global medical terminology software market size is expected to reach USD 2.34 billion by 2030, registering a CAGR of 10.1% during the forecast period, according to a new report by Grand View Research, Inc.

The General Pharmaceutical Council (GPhC) has published the results of the common registration assessment for aspiring pharmacists held on 2 November, 2023. An overall pass rate of 66 per cent was recorded this year, as compared to 56 per cent in 2022 and 61 per cent in 2021. A total of 1,067 candidates took the registration assessment, held jointly by the GPhC and Pharmaceutical Society of Northern Ireland (PSNI), of which 700 candidates cleared the assessment In 2022, 937 candidates sat the registration assessment of which 525 passed the assessment. Commenting on the results, GPhC Director of Education and Standards, Mark Voce, said: "I would like to congratulate all those who passed the November registration assessment and I look forward to them joining our register to continue to the next stage of their career. "There will be candidates who unfortunately did not pass the assessment. If this is the case, the information on our website outlines all the possible options of what to do next.

The International Pharmaceutical Federation (FIP) launched a report on pharmacy-led common ailment schemes. The data was collected from 24 countries, including case studies from nine countries. It highlighted the growing demand for care models for ageing populations and the increase in chronic non-communicable diseases. Pharmacists had been managing the stress, including prescribing authority and provision of medicinal treatments. Paul Sinclair AM, Global President of FIP, said, "I believe this report is both a foundation and a catalyst - a foundation on which FIP and our member organizations could base initial strategies and a catalyst to drive us to seek even more diverse and comprehensive insights in the future.

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

The Department of Health (DoH) in Northern Ireland has published a new Strategic Plan for Community Pharmacy, highlighting the vision and key priorities for the sector over the next 10 years. Co-developed by the DoH and Community Pharmacy Northern Ireland (CPNI), the representative body for community pharmacy owners, the plan aims to fully realise the potential of community pharmacy services to support better health outcomes from medicines and prevent illness. The vision outlined in the plan sees community pharmacies offering more clinical services, leveraging the skills of their teams to provide the public with safe, convenient, and faster access to care. According to DOH, the vision will be realised through four major reform programmes focusing on services, legislation, workforce, and digital enablers, alongside six strategic priorities. Together, these initiatives are anticipated to transform the role of community pharmacy within the Health and Social Care (HSC). Health Minister Robin Swann has extended his support to the new Community Pharmacy Strategic Plan, which builds on the previously agreed 3-year community pharmacy commissioning plan.

The British Association of Dermatologists (BAD) has raised concerned about rising cases of scabies in the UK, and suggested that the current shortage of medicines is contributing to the outbreak. Usually, this skin condition is treated using topical creams or oral medication in more severe cases, but shortage of scabies drugs has been reported since May 2023. Both permethrin 5% cream and malathion liquid, which are two main topical treatments for scabies, are in limited supply in the U.K. Paula Geanau, a spokesperson for BAD, told Fox News Digital on Friday (19 January) that the rate of scabies is double the seasonal average, with three cases per 100,000 of the population recorded at the end of November by the Royal College of GPs.

The Royal Pharmaceutical Society (RPS), professional membership body for pharmacists and pharmacy, has published its manifesto for the general election, highlighting key issues facing the next government after the election on July 4. Local candidates are urged to recognise and support the vital role pharmacists play in supporting people's health. The RPS teams are gearing up to influence government policy in various crucial areas. Their key asks include: Ensuring Secure Patient Access to Medicines Supporting a Better-Connected NHS Enhancing Accessible Prescribing in Local Communities Maximizing Health Improvement through Locally Accessible Pharmacy Teams Supporting the Workforce to Deliver Patient Care Unlocking the Potential of New Advances in Medicines Supporting the UK's Global Position in Science and Research Acknowledging the efforts of pharmacists and their teams, Professor Claire Anderson, President of the RPS, noted that they are "working incredibly hard to maintain patient access to care amid workforce challenges, medicines shortages and financial pressures."